Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

The aims of this study were to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetics of irinotecan given with oral R115777 (tipifarnib), a farnesyl protein transferase inhibitor. Patients were treated with escalating doses of irinotecan with interval-modulated dosing of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sparreboom, A, Kehrer, D F S, Mathijssen, R H J, Xie, R, de Jonge, M J A, de Bruijn, P, Planting, A S T, Eskens, F A L M, Verheij, C, de Heus, G, Klaren, A, Zhang, S, Verhaeghe, T, Palmer, P A, Verweij, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409716/
https://www.ncbi.nlm.nih.gov/pubmed/15083177
http://dx.doi.org/10.1038/sj.bjc.6601732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409716/
https://www.ncbi.nlm.nih.gov/pubmed/15083177
http://dx.doi.org/10.1038/sj.bjc.6601732

Ejemplares similares